BICARA THERAPEUTICS INC (BCAX) Forecast, Price Target & Analyst Ratings

NASDAQ:BCAX • US0554771032

Current stock price

21.47 USD
+0.97 (+4.73%)
At close:
21.47 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BICARA THERAPEUTICS INC (BCAX).

Forecast Snapshot

Consensus Price Target

Price Target
$29.86
+ 39.07% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.66
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$29.86
Upside
+ 39.07%
From current price of $21.47 to mean target of $29.86, Based on 20 analyst forecasts
Low
$11.11
Median
$30.60
High
$50.40

Price Target Revisions

1 Month
0.00%
3 Months
-10.13%

Price Target Summary

20 Wall Street analysts provided a forecast for the next 12 months for BCAX. The average price target is 29.86 USD. This implies a price increase of 39.07% is expected in the next year compared to the current price of 21.47.
The average price target has been revised downward by 10.13% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BCAX Current Analyst RatingBCAX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

BCAX Historical Analyst RatingsBCAX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
82.00%
BCAX was analyzed by 20 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about BCAX.
In the previous month the buy percentage consensus was at a similar level.
BCAX was analyzed by 20 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-31CitizensReiterate Market Outperform -> Market Outperform
2026-03-31WedbushReiterate Outperform -> Outperform
2026-03-31Wells FargoMaintains Equal-Weight -> Equal-Weight
2026-03-31Goldman SachsMaintains Neutral -> Neutral
2026-03-31HC Wainwright & Co.Maintains Buy -> Buy
2026-03-25B of A SecuritiesInitiate Buy
2026-01-29CitizensInitiate Market Outperform
2026-01-13WedbushReiterate Outperform -> Outperform
2026-01-08BTIGInitiate Buy
2025-12-18MizuhoInitiate Neutral
2025-11-11Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-08-22HC Wainwright & Co.Maintains Buy -> Buy
2025-08-19Piper SandlerInitiate Overweight
2025-05-23Wells FargoUpgrade Underweight -> Equal-Weight
2025-05-16HC Wainwright & Co.Maintains Buy -> Buy
2025-04-17Wells FargoInitiate Underweight
2025-04-07HC Wainwright & Co.Maintains Buy -> Buy
2025-03-13Cantor FitzgeraldReiterate Overweight -> Overweight
2025-02-12WedbushReiterate Outperform -> Outperform
2025-02-06WedbushInitiate Outperform
2025-01-27HC Wainwright & Co.Maintains Buy -> Buy
2024-12-06HC Wainwright & Co.Initiate Buy
2024-10-08TD CowenInitiate Buy
2024-10-08Cantor FitzgeraldInitiate Overweight
2024-10-08StifelInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.66
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
2.98%
Number of Analysts
15

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
2.19%

Next Earnings Summary

BCAX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.66 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
BCAX revenue by date.BCAX revenue by date.
N/AN/AN/AN/AN/A
1,626.10%		N/A
173.79%		N/A
60.56%		N/A
53.58%		N/A
25.62%
EBITDA
YoY % growth
BCAX ebitda by date.BCAX ebitda by date.
-37.646M-39.87M
-5.91%		-82.333M
-106.50%		N/A
-84.60%		N/A
-22.79%		N/A
-12.48%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
BCAX ebit by date.BCAX ebit by date.
-37.656M-39.889M
-5.93%		-82.389M
-106.55%		N/A
-90.43%		N/A
-0.22%		N/A
-39.28%		N/A
-7.27%		N/A
26.41%		N/A
142.28%		N/A
309.20%		N/A
92.74%		N/A
37.11%
Operating Margin
BCAX operating margin by date.BCAX operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BCAX eps by date.BCAX eps by date.
N/AN/AN/A-2.53
4.64%		N/A
-21.96%		N/A
-6.40%		N/A
26.99%		N/A
24.47%		N/A
84.08%		N/A
911.79%		N/A
103.42%		N/A
-3.54%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28
EPS
Q2Q % growth		-0.66
2.98%		-0.66
-31.31%		-0.70
-5.01%		-0.73
-7.50%		-0.97
-46.88%		-0.93
-41.99%		-1.05
-49.18%		-1.17
-60.46%		-0.74
24.11%		-0.69
26.37%		-0.45
56.85%
Revenue
Q2Q % growth		N/AN/AN/A
EBITDA
Q2Q % growth		-41.993M
-0.54%		-43.262M
-35.28%		-44.938M
-10.65%		-45.843M
-17.60%		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-42.64M
-2.04%		-44.694M
-39.59%		-47.661M
-17.17%		-50.171M
-18.55%		N/AN/AN/AN/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
1.72%
EPS Next 5 Year
13.53%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-38.35%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BICARA THERAPEUTICS INC / BCAX Forecast FAQ

What is the average price target for BICARA THERAPEUTICS INC (BCAX) stock?

20 analysts have analysed BCAX and the average price target is 29.86 USD. This implies a price increase of 39.07% is expected in the next year compared to the current price of 21.47.

When does BICARA THERAPEUTICS INC (BCAX) report earnings?

BICARA THERAPEUTICS INC (BCAX) will report earnings on 2026-05-11.

Can you provide the consensus estimates for BICARA THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of BICARA THERAPEUTICS INC (BCAX) is -0.66 USD and the consensus revenue estimate is 0 USD.